all bombay times print stories are available on
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
.
i know major media won�t investigate medically-caused death numbers, because i�ve published reports for years, and i�ve contacted news people with the facts; and nothing happens.
.
of all car-t cell trials registered since 2001, more than half are being conducted in china.
.